Completed NA INTERVENTIONAL 1-arm NCT04560270

CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer

KRAS (Kirsten Rat Sarcoma) Mutant CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Locally Advanced and Metastatic PANcreatic Cancer

Sponsor: Poitiers University Hospital

Conditions Circulating Tumor DNA KRAS Mutation-Related Tumors Pancreatic Cancer

Interventions Blood samples

Updated 4 times since 2020 Last updated: Sep 17, 2020 Started: Apr 25, 2016 Primary completion: Jun 28, 2019 Completion: Nov 15, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Circulating Tumor DNA and KRAS Mutation-Related Tumors and is currently completed. Poitiers University Hospital leads this study, which shows 4 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Oct 2020 — Jan 2021 [monthly]

Completed NA

First recorded

Apr 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Poitiers University Hospital

Data source: Poitiers University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.